Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001689375-24-000063
Filing Date
2024-11-05
Accepted
2024-11-05 07:12:26
Documents
68
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q trda-20240930.htm   iXBRL 10-Q 1597623
2 EX-31.1 trda-20240930x10qex311.htm EX-31.1 10870
3 EX-31.2 trda-20240930x10qex312.htm EX-31.2 10893
4 EX-32.1 trda-20240930x10qex321.htm EX-32.1 7226
  Complete submission text file 0001689375-24-000063.txt   6169473

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trda-20240930.xsd EX-101.SCH 33394
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT trda-20240930_cal.xml EX-101.CAL 59525
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT trda-20240930_def.xml EX-101.DEF 182478
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trda-20240930_lab.xml EX-101.LAB 512162
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trda-20240930_pre.xml EX-101.PRE 358402
71 EXTRACTED XBRL INSTANCE DOCUMENT trda-20240930_htm.xml XML 674638
Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Filer) CIK: 0001689375 (see all company filings)

EIN.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40969 | Film No.: 241425609
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)